妇科恶性肿瘤术后骨盆剂量限定放疗同步化疗的临床研究  

CLINICAL RESEARCH ON PELVIC LIMITED RADIOTHERAPY AND CONCURRENT CHEMOTHERAPY AFTER SURGERY FOR GYNECOLOGICAL MALIGNANT TUMORS

作　　者：杨爱华 陈维燕 刘婷 李喆 左东华 YANG Ai-hua;CHEN Wei-yan;LIU Ting;LI Zhe;ZUO Dong-hua(Linyi City Tumor Hospital,Linyi,China 276000)

机构地区：[1]临沂市肿瘤医院,山东临沂276000

出　　处：《山东医学高等专科学校学报》2023年第1期15-18,共4页Journal of Shandong Medical College

摘　　要：目的探讨妇科恶性肿瘤术后放疗方法。方法回顾性收集70例宫颈癌及44例子宫内膜癌患者临床资料,术后根据放疗是否进行骨盆剂量限定分为PBMS-IGRT、IGRT两组,各57例。两组均行盆腔外照射联合每周顺铂化疗,计划靶体积剂量50.4 Gy。PBMS-IGRT组勾画骨盆并给予单独限量:骨盆V10≤90%,V20≤75%。结果PBMS-IGRT组急性血液学不良反应明显减轻(P<0.05);骨盆V5、V10、V20、V30值均低于IGRT组;两组其他比较均无统计学意义。结论宫颈癌、子宫内膜癌术后行盆腔同步放化疗患者,PBMS-IGRT组较IGRT组具有更高的安全性。Objective To explore the postoperative radiotherapy for gynecological malignant tumors.Methods The clinical data of 70 cases of cervical cancer and 44 cases of endometrial cancer were retrospectively collected.The patients were divided into the PBMS-IGRT and IGRT groups according to whether or not using the pelvic dose limitation of radiotherapy,with 57 cases in each group.Both groups underwent external pelvic irradiation and weekly cisplatin chemotherapy,and the planned target volume dose was 50.4 Gy.The PBMS-IGRT group had the pelvis delineated and was given separate limits:the pelvic V10≤90%and V20≤75%.Results The acute hematological adverse reactions in the PBMS-IGRT group were significantly relieved(P<0.05).The values of pelvic V5、V10、V20 and V30 were lower in the PBMS-IGRT group than those in the IGRT group.No other significant differences between the two groups were found.Conclusion Higher safety can be obtained in the PBMS-IGRT group than in the IGRT group in treating patients with cervical and endometrial cancer undergoing pelvic limited radiotherapy and concurrent chemotherapy after surgery.

关 键 词：宫颈癌 子宫内膜癌 骨盆剂量限定 

分 类 号：R737.3[医药卫生—肿瘤]